News & Media
News Updates
New York, June 20, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it
New York, June 18, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it
New York, June 13, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the implementation
New York, June 12, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition
NEW YORK, May 29, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful
NEW YORK, May 23, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today unveiled key performance
Innovative Fingerprint Drug Screening Solution Showcased at the UK’s Premier Health and Safety Event
NEW YORK, May 17, 2024 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful
Year-over-year revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024. Cash and cash equivalents as of March 31, 2024, was $9.40 million. Commenced FDA 510(k) clinical
Traditional drug tests can be intrusive, undignified, and uncomfortable for both test takers and administrators. The Intelligent Fingerprinting Drug Screening System detects commonly abused drugs via fingertip sweat analysis, eliminating the need for invasive and unpleasant urine, saliva, or blood collection.
Year-over-year unaudited revenue increased 80% for the fiscal third quarter and 193% for the nine months ended March 31, 2024, with highest quarterly cartridge sales since 2022 Intelligent Fingerprinting acquisition
Non-invasive health diagnostics are on the rise, and fingerprint testing technology is at the forefront. This article explores the history and ongoing development of fingerprint sweat analysis and its potential
NEW YORK, April 11, 2024 – Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the broadening
Media
